CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results